Product
BRV
1 clinical trial
1 indication
Indication
Unverricht-Lundborg DiseaseClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseStatus: Completed, Estimated PCD: 2008-01-01